Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Thyroid cancer
Stage/Subtype:  recurrent thyroid cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-13 of 13 for your search:
Start Over
Crolibulin and Cisplatin in Treating Patients with Recurrent or Metastatic Solid Tumors That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 90
Trial IDs: 11-C-0027, NCI-2013-01471, 110027, 343865, P10677, NCT01240590
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PLX120-03, NCI-2015-00720, NCT02428712
Pasireotide and Everolimus in Treating Patients with Thyroid Cancer Refractory to Radioiodine
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WCI1777-09, NCI-2011-03377, IRB00041909, NCT01270321
Biomarkers in Predicting Response in Patients with Locally Advanced Thyroid Cancer Receiving Vemurafenib before Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012-0471, NCI-2012-02171, 00000363, NCT01709292
Dabrafenib with or without Trametinib in Treating Patients with Recurrent Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 12064, NCI-2012-01700, 2012C0074, NCCNGSK20008, NCT01723202
Sorafenib Tosylate with or without Everolimus in Treating Patients with Advanced, Radioactive Iodine Refractory Thyroid Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: A091302, NCI-2014-00623, NCT02143726
Inolitazone Dihydrochloride With or Without Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: A091305, NCI-2014-00686, NCT02152137
Trametinib in Increasing Tumoral Iodine Incorporation in Patients with Recurrent or Metastatic Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-157, NCI-2014-01106, 9446, NCT02152995
Dabrafenib and Lapatinib Ditosylate in Treating Patients with Refractory Thyroid Cancer That Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-061, NCI-2013-01748, 9354, NCT01947023
Dabrafenib and Radioactive Iodine in Treating Patients With Papillary Thyroid Carcinoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-337, NCI-2012-00817, NCT01534897
Vemurafenib and Iodine I 131 in Treating Patients with BRAF Mutant, Radioiodine-Refractory Thyroid Cancer
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 14-031, NCI-2014-01210, NCT02145143
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: E7080-G000-398, NCI-2014-01802, NCT02211222
Start Over